LONDON, UK, Monday, April 23, 2007 - SkyePharma PLC (LSE:SKP; NASDAQ: SKYE) today announces that regulatory approval has been received in France for ropinirole prolonged release tablets (which will be marketed as REQUIP™ LP (1) in France). The new prolonged release tablet of ropinirole is taken once daily, and is indicated for the treatment of Parkinson’s disease (PD). SkyePharma’s partner for the product, GlaxoSmithKline has also received approval in Slovakia, Slovenia, Latvia, Estonia and Canada, and plans to gain further marketing authorisations in other countries.
